• About us
• Contact

Advertisement

Organisation › Details

HBM BioCapital Management GmbH

HBM Partners is among the global leaders in healthcare-focused investing with approximately USD 800 million under management. HBM focuses on development-stage, growth and buy-out financings of private companies as well as investments in public companies. HBM Partners advises HBM BioVentures AG, HBM BioCapital and further specialized private-equity and public-equity funds. Since 2001, HBM Partners has realized over 40 IPOs and trade sales from its portfolios of healthcare and life sciences companies. *

 

	Start	2003-01-01 existent
	Group	HBM (Group)
	Industry	venture capital
	Region	Heidelberg
	Country	Germany
	City	69120 Heidelberg
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-12-30

Advertisement

More documents for HBM (Group)

• [1] HBM Healthcare Investments Ltd.. (5/10/22). "Press Release: Pfizer to Acquire HBM Portfolio Company Biohaven Pharmaceuticals in USD 11.6 Billion Deal". Zug....
• [2] eGenesis Inc.. (3/2/21). "Press Release: eGenesis Announces $125 Million Series C Financing". Cambridge, MA....
• [3] IO Biotech ApS. (1/13/21). "Press Release: IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology". Copenhagen....
• [4] Polyneuron Pharmaceuticals AG. (9/16/20). "Press Release: Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million". Basel....
• [5] Arcutis Biotherapeutics, Inc.. (10/21/19). "Press Release: Arcutis Announces the Completion of $94.5 Million Series C Financing". Westlake Village, CA....
• [6] Adrenomed AG. (11/26/18). "Press Release: Adrenomed Closes EUR 24 M Financing Led by Wellington and HBM". Hennigsdorf, Munich & Zug....
• [7] SphingoTec GmbH. (10/8/18). "Press Release: SphingoTec Raises €20 Million from HBM and Wellington Partners". Hennigsdorf....
• [8] Homology Medicines, Inc.. (8/1/17). "Press Release: Homology Medicines Announces $83.5 Million Series B Financing to Advance Lead Development Candidate and AMEnDR In Vivo Gene Editing Technology". Bedford, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.